Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Prime Medicine Q1 2024 GAAP EPS $(0.44) Beats $(0.47) Estimate

Author: Benzinga Newsdesk | May 10, 2024 08:02am
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.47) by 6.38 percent.

Posted In: PRME